Target intelligence / Profile preview

Chromosome 16 open reading frame 86 (C16orf86)

Target
C16orf86
Molecular classification
Other (No clear assignment to standard categories like receptor, enzyme, transporter, transcription factor, ion channel, or histone modifier due to unknown function)
01

Overview

C16orf86 (Chromosome 16 open reading frame 86) encodes a protein of unknown function in humans. It is annotated as a protein-coding gene, but as of now, no molecular function, mechanism of action, or protein class assignment is established. C16orf86 has not been characterized as a receptor, enzyme, transporter, or any standard molecular target type. Current evidence is limited to gene expression data suggesting its possible inclusion in multi-gene transcriptomic panels for cancer prognosis, particularly in pancreatic adenocarcinoma, but it is not known to have direct disease roles or therapeutic relevance. There are no reported drug interactions, no functional domains, and no described mechanisms of action[1][2][3][5]. In summary: C16orf86 is a protein-coding gene with unclear biological and disease relevance, lacking evidence as a therapeutic target, and currently classified as an “uncharacterized protein.”

Other names
C16orf86FLJ41802Uncharacterized protein C16orf86Chromosome 16 open reading frame 86
02

Mechanism of action

None (No mechanisms of action are described due to lack of drugs targeting C16orf86)

03

Biological functions

Other (No established biological functions as of current data. It is annotated as a protein-coding gene, but its role in cellular processes is not characterized)
04

Disease associations

Other (Limited data; there are reports of gene expression signatures including C16orf86 in pancreatic adenocarcinoma [PAAD], suggesting possible relevance to cancer biomarker panels; however, its role in disease pathophysiology is not established)
05

Safety considerations

None reported (No known therapeutic interventions or safety profile information)
06

Interacting drugs

None (No known drugs are reported to interact with C16orf86)
07

Biomarkers

C16orf86 has been reported within transcriptomic gene signatures associated with overall survival in pancreatic adenocarcinoma (PAAD); its inclusion suggests possible relevance in gene expression panels, but not as a validated standalone biomarker

Beyond the preview

Go deeper on Chromosome 16 open reading frame 86 (C16orf86).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromosome 16 open reading frame 86 (C16orf86).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call